WO1998050554A3 - Enterococcus faecalis polynucleotides and polypeptides - Google Patents

Enterococcus faecalis polynucleotides and polypeptides Download PDF

Info

Publication number
WO1998050554A3
WO1998050554A3 PCT/US1998/008959 US9808959W WO9850554A3 WO 1998050554 A3 WO1998050554 A3 WO 1998050554A3 US 9808959 W US9808959 W US 9808959W WO 9850554 A3 WO9850554 A3 WO 9850554A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
enterococcus faecalis
enterococcus
antibodies
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/008959
Other languages
French (fr)
Other versions
WO1998050554A2 (en
Inventor
Charles A Kunsch
Gil H Choi
Camella Bailey
Alex Hromockyj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to AU72793/98A priority Critical patent/AU735444B2/en
Priority to CA002289116A priority patent/CA2289116A1/en
Priority to EP98920160A priority patent/EP1002090A2/en
Priority to JP54828998A priority patent/JP2002516571A/en
Publication of WO1998050554A2 publication Critical patent/WO1998050554A2/en
Publication of WO1998050554A3 publication Critical patent/WO1998050554A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to novel genes from Enterococcus faecalis and the polypeptides they encode. Also provided are vectors, host cells, antibodies and methods for producing the same. The invention additionally relates to diagnostic methods for detecting Enterococcus nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by Enterococcus.
PCT/US1998/008959 1997-05-06 1998-05-04 Enterococcus faecalis polynucleotides and polypeptides Ceased WO1998050554A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU72793/98A AU735444B2 (en) 1997-05-06 1998-05-04 (Enterococcus faecalis) polynucleotides and polypeptides
CA002289116A CA2289116A1 (en) 1997-05-06 1998-05-04 Enterococcus faecalis polynucleotides and polypeptides
EP98920160A EP1002090A2 (en) 1997-05-06 1998-05-04 $i(ENTEROCOCCUS FAECALIS) POLYNUCLEOTIDES AND POLYPEPTIDES
JP54828998A JP2002516571A (en) 1997-05-06 1998-05-04 Enterococcus faecalis polynucleotides and polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4403197P 1997-05-06 1997-05-06
US60/044,031 1997-05-06
US4665597P 1997-05-16 1997-05-16
US60/046,655 1997-05-16
US6600997P 1997-11-14 1997-11-14
US60/066,009 1997-11-14

Publications (2)

Publication Number Publication Date
WO1998050554A2 WO1998050554A2 (en) 1998-11-12
WO1998050554A3 true WO1998050554A3 (en) 1999-04-01

Family

ID=27366427

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1998/008985 Ceased WO1998050555A2 (en) 1997-05-06 1998-05-04 Enterococcus faecalis polynucleotides and polypeptides
PCT/US1998/008959 Ceased WO1998050554A2 (en) 1997-05-06 1998-05-04 Enterococcus faecalis polynucleotides and polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008985 Ceased WO1998050555A2 (en) 1997-05-06 1998-05-04 Enterococcus faecalis polynucleotides and polypeptides

Country Status (8)

Country Link
US (3) US6448043B1 (en)
EP (2) EP0981625A2 (en)
JP (2) JP2002529046A (en)
KR (2) KR20010012223A (en)
CN (1) CN1268178A (en)
AU (2) AU735444B2 (en)
CA (2) CA2289116A1 (en)
WO (2) WO1998050555A2 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946157B2 (en) 2010-05-03 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
US8986681B2 (en) 2010-04-27 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US9347053B2 (en) 2010-05-27 2016-05-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
US9399770B2 (en) 2010-10-06 2016-07-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
US9404104B2 (en) 2010-05-04 2016-08-02 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of P38 multi-tRNA synthetase complex
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9574187B2 (en) 2010-05-04 2017-02-21 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905670B2 (en) 1995-03-28 2005-06-14 The General Hospital Corporation Methods of screening compounds useful for prevention of infection or pathogenicity
US5834276A (en) * 1996-04-18 1998-11-10 Smithkline Beecham Corporation Asparaginyl TRNA synthetase polynucleotides of streptococcus
US6165989A (en) 1996-05-14 2000-12-26 Smithkline Beecham Corporation Era of Streptococcus pneumoniae
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
EP1017707A4 (en) * 1997-08-29 2004-04-28 Human Genome Sciences Inc 29 HUMAN SECRETED PROTEINS
CA2365523A1 (en) * 1999-04-15 2000-10-26 The Regents Of The University Of California Identification of sortase gene
US7101692B2 (en) 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
US6908994B1 (en) * 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
US6589738B1 (en) 1999-11-09 2003-07-08 Elitra Pharmaceuticals, Inc. Genes essential for microbial proliferation and antisense thereto
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
JP2003523207A (en) 2000-01-25 2003-08-05 ジェネンテック・インコーポレーテッド LIV-1-related proteins, polynucleotides encoding them, and their use in treating cancer
US7078584B2 (en) 2000-03-17 2006-07-18 The General Hospital Corporation Salmonella typhimurium-infected Caenorhabditis elegans for identifying inhibitors of infection
KR20020097200A (en) * 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 Identification of essential genes in prokaryotes
US7112716B2 (en) 2000-04-06 2006-09-26 The General Hospital Corporation Methods for screening and identifying host pathogen defense genes
EP1360315A2 (en) * 2000-04-06 2003-11-12 PHARMACIA & UPJOHN COMPANY Antimicrobial methods and materials
AU2001253508A1 (en) * 2000-04-14 2001-10-30 Phytera, Inc. Mdr efflux pumps
AU2001269527A1 (en) * 2000-07-18 2002-01-30 Center For Advanced Science And Technology Incubation, Ltd. Isopentenyl pyrophosphate isomerase
US7892552B2 (en) 2001-08-08 2011-02-22 University Of Utah Research Foundation Group B Streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
AU2001281168A1 (en) 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
US7349808B1 (en) 2000-09-06 2008-03-25 Egenomics, Inc. System and method for tracking and controlling infections
US20020120408A1 (en) * 2000-09-06 2002-08-29 Kreiswirth Barry N. System and method for tracking and controlling infections
ATE439372T1 (en) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic NUCLEIC ACIDS AND PROTEINS OF GROUP A AND B STREPTOCOCICS
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
WO2003056295A2 (en) * 2001-07-18 2003-07-10 The General Hospital Corporation Enterococcal virulence factors
US6696254B2 (en) * 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
AU2003250683A1 (en) * 2002-07-31 2004-02-16 Affinium Pharmaceuticals, Inc. Peptidyl-trna hydrolase of enterococcus faecalis
WO2004013167A2 (en) * 2002-08-01 2004-02-12 Affinium Pharmaceuticals, Inc. Purified polypeptides from enterococcus faecalis
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
EP1540559B1 (en) * 2002-09-13 2013-02-27 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
WO2004042044A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial guanylate kinases
WO2004042045A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial thymidylate kinases
WO2004042043A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial ribulose-phosphate 3-epimerases
WO2004053156A1 (en) * 2002-12-06 2004-06-24 Innogenetics N.V. Detection, identification and differentiation of eubacterial taxa using a hybridization assay
JP4399211B2 (en) * 2002-12-21 2010-01-13 株式会社ハイニックスセミコンダクター Biosensor
CN102304527A (en) * 2003-05-30 2012-01-04 英特塞尔股份公司 Enterococcus antigens
JP4875490B2 (en) * 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Immunogenic composition for Streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
US20060165716A1 (en) * 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006042027A2 (en) * 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
EP2371967B1 (en) 2005-03-18 2015-06-03 DSM IP Assets B.V. Production of carotenoids in oleaginous yeast and fungi
DE602005020859D1 (en) * 2005-09-06 2010-06-02 Biogreen As DECALUATED FLAX SEEDS AND ITS BY-PRODUCT AND ITS MANUFACTURE AND USE
US20070059714A1 (en) * 2005-09-12 2007-03-15 Birgit Strommenger Detection of presence and antibiotic susceptibility of enterococci
ATE522541T1 (en) * 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
US8691555B2 (en) 2006-09-28 2014-04-08 Dsm Ip Assests B.V. Production of carotenoids in oleaginous yeast and fungi
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
BRPI0821240B8 (en) 2007-12-21 2022-10-04 Novartis Ag mutant forms of streptolysin o
WO2010030790A2 (en) * 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
CN107126557A (en) 2009-06-29 2017-09-05 健诺西生物科学公司 Vaccines and compositions against streptococcus pneumoniae
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
WO2012100234A1 (en) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
CN102286417B (en) * 2011-09-09 2013-04-10 宜春强微生物科技有限公司 High-density Enterococcus faecalis and fermentation culture technology thereof
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
AU2012368189B2 (en) 2011-12-29 2017-08-31 Atyr Pharma, Inc. Aspartyl-tRNA synthetase-Fc conjugates
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2017172260A1 (en) 2016-03-31 2017-10-05 Ngm Bioparmaceuticals, Inc. Binding proteins and methods of use thereof
CN106244714B (en) * 2016-09-23 2019-09-24 山西大学 A kind of genetic chip of bacillus megaterium specific detection
CN106978380A (en) * 2016-12-14 2017-07-25 天津科技大学 One plant height xylose patience Friedlander's bacillus strain and its construction method
CN110536694A (en) 2017-04-20 2019-12-03 Atyr 医药公司 Compositions and methods for treating pulmonary inflammation
CN107526942B (en) * 2017-07-18 2021-04-20 中山大学 A Reverse Retrieval Method for Biomics Sequence Data
KR101996079B1 (en) * 2017-10-13 2019-07-03 연세대학교 원주산학협력단 Composition for preventing or treating hair loss comprising enterococcus faecalis
CN108776221B (en) * 2018-06-06 2020-07-31 中国农业大学 A kit for simultaneous detection of avian leukemia virus antibodies and Salmonella pullorum antibodies
CN109182240B (en) * 2018-09-18 2021-06-25 绿康生化股份有限公司 Application of bacillus licheniformis DW2 delta phoP in bacitracin production
CN110423832A (en) * 2019-08-28 2019-11-08 华南理工大学 A PCR detection primer for Listeria monocytogenes based on the specific gene target lmo0160
CN110964672B (en) * 2019-12-29 2022-09-02 江南大学 Pediococcus pentosaceus CCFM1104, and fermented food and application thereof
CN114686562B (en) * 2020-12-28 2024-04-30 广东菲鹏生物有限公司 Compositions, kits, methods and systems for nucleic acid sample amplification
CN114214445A (en) * 2021-12-29 2022-03-22 自然资源部第一海洋研究所 Rapid quantitative detection method for living pathogenic bacteria in ship ballast water
CN114540521B (en) * 2022-03-23 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) Lactobacillus plantarum 84-3 specific molecular target with blood sugar and blood fat reducing effects and detection method thereof
US20250269004A1 (en) * 2022-04-18 2025-08-28 Vaxcyte, Inc. Enterococcus faecalis vaccine and uses thereof
WO2023210800A1 (en) * 2022-04-28 2023-11-02 国立大学法人東京大学 Bacteriolytic agent against enterococcus faecalis
CN115322975B (en) * 2022-06-16 2023-04-25 扬州大学 Mutant of enterobacter ludwigii oxidoreductase and application thereof
CN116199750A (en) * 2023-01-06 2023-06-02 吉林大学 Ribosomal protein S11, preparation method and application thereof in vaccine adjuvant
CN117778439A (en) * 2024-01-03 2024-03-29 天津大学 A genetically engineered bacterium that produces lincomycin and its construction method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652291A1 (en) * 1992-07-07 1995-05-10 Fuso Pharmaceutical Industries Ltd. Probe for diagnosing infectious disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2218741A1 (en) 1995-04-21 1996-10-24 Johns Hopkins University Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
US6537773B1 (en) 1995-06-07 2003-03-25 The Institute For Genomic Research Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof
CA2503110A1 (en) 1999-05-10 2000-11-16 Rebecca L. Rich Collagen-binding proteins from enterococcal bacteria

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652291A1 (en) * 1992-07-07 1995-05-10 Fuso Pharmaceutical Industries Ltd. Probe for diagnosing infectious disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURNIE J P & CLARK I: "Diagnosing endocarditis with the cloned 112 kDa antigen of Enterococcus faecalis.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 123, 1989, pages 217 - 225, XP002074342 *
CLARK I M ET AL: "ISOLATION AND SEQUENCE DETERMINATION OF AN IMMUNODOMINANT ANTIGEN FROM ENTEROCOCCUS FAECALIS", SERODIAGNOSIS AND IMMUNOTHERAPY IN INFECTIOUS DISEASE, vol. 5, no. 2, July 1993 (1993-07-01), pages 85 - 92, XP002050866 *
EVERS S & COURVALIN P: "Regulation of VanB-Type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583.", JOURNAL OF BACTERIOLOGY, vol. 178, 1996, pages 1302 - 1309, XP002073904 *
LOWE A M ET AL: "Cloning of an Enterococcus faecalis endocarditis antigen: homology with adhesins from some oral Streptococci.", INFECTION AND IMMUNITY, vol. 63, no. 2, February 1995 (1995-02-01), pages 703 - 706, XP002073905 *
XU Y ET AL: "Enterococcus faecalis antigens in human infections.", INFECTION AND IMMUNITY, vol. 65, no. 10, October 1997 (1997-10-01), pages 4207 - 4215, XP002073906 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540629B2 (en) 2010-04-26 2017-01-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase
US8980253B2 (en) 2010-04-26 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
US8961960B2 (en) 2010-04-27 2015-02-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US9580706B2 (en) 2010-04-27 2017-02-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
US8986681B2 (en) 2010-04-27 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
US9320782B2 (en) 2010-04-28 2016-04-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
US9556425B2 (en) 2010-04-29 2017-01-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
US9034320B2 (en) 2010-04-29 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
US9593323B2 (en) 2010-05-03 2017-03-14 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
US9422538B2 (en) 2010-05-03 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetasis
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US8946157B2 (en) 2010-05-03 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9593322B2 (en) 2010-05-03 2017-03-14 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
US9574187B2 (en) 2010-05-04 2017-02-21 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
US9404104B2 (en) 2010-05-04 2016-08-02 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of P38 multi-tRNA synthetase complex
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
US9347053B2 (en) 2010-05-27 2016-05-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
US9322009B2 (en) 2010-06-01 2016-04-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9315794B2 (en) 2010-07-12 2016-04-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9399770B2 (en) 2010-10-06 2016-07-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Also Published As

Publication number Publication date
US20030017495A1 (en) 2003-01-23
JP2002529046A (en) 2002-09-03
KR20010012236A (en) 2001-02-15
US20050043528A1 (en) 2005-02-24
WO1998050554A2 (en) 1998-11-12
EP0981625A2 (en) 2000-03-01
JP2002516571A (en) 2002-06-04
US20020045737A1 (en) 2002-04-18
CN1268178A (en) 2000-09-27
AU745787B2 (en) 2002-03-28
AU735444B2 (en) 2001-07-05
US6448043B1 (en) 2002-09-10
AU7279398A (en) 1998-11-27
US6913907B2 (en) 2005-07-05
AU7280598A (en) 1998-11-27
CA2289116A1 (en) 1998-11-12
WO1998050555A2 (en) 1998-11-12
KR20010012223A (en) 2001-02-15
CA2288944A1 (en) 1998-11-12
EP1002090A2 (en) 2000-05-24
WO1998050555A3 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
WO1998018930A3 (en) Streptococcus pneumoniae antigens and vaccines
WO1997033909A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
CA2295999A1 (en) Nik proteins, nucleic acids and methods
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
SG108208A1 (en) Connective tissue growth factor
WO1999064592A3 (en) Green fluorescent proteins for measuring the ph of a biological sample
WO2001040497A3 (en) Method for obtaining nucleic acids from an environment sample
WO2001004264A3 (en) Atherosclerosis-associated genes
AU3025597A (en) Method of providing novel dna sequences
IL233391A0 (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
WO1999047639A3 (en) Staphylococcus aureus genes and polypeptides
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
EP1897949A3 (en) Human interleukin-B50. Therapeutic uses
WO2000012678A3 (en) Staphylococcus aureus genes and polypeptides
WO2002000722A3 (en) Human calcium channels (48000; 52920) and uses thereof
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO1998011226A3 (en) Mammalian chemokines, related reagents
CA2336261A1 (en) Cyclin e2 genes and proteins
WO1998023750A3 (en) Mammalian chemokines
WO1998018822A3 (en) Novel human lim proteins
AU4136797A (en) Novel semaphorin gene: semaphorin y
CA2250263A1 (en) Human netrin-1
AU6423198A (en) Probe for diagnosis of infectious disease caused by (Streptococcus pyogenes)
WO1999019491A3 (en) Human dnax interleukin-40 (dil-40)
WO2001036463A3 (en) Genes specifically expressed in human dendritic cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98806929.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2289116

Country of ref document: CA

Ref document number: 2289116

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997010185

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 72793/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998920160

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998920160

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997010185

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 72793/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998920160

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997010185

Country of ref document: KR